Nu-Med Plus (NUMD) Cash & Equivalents Growth (3y) (2014 - 2025)
Nu-Med Plus (NUMD) Cash & Equivalents Growth (3y) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.90 Bn | 193.29 Bn | 7.27 Bn | -13.31% |
| 2 | Stryker | 129.12 Bn | 125.64 Bn | 4.50 Bn | 34.27% |
| 3 | Medtronic | 119.32 Bn | 110.10 Bn | 6.41 Bn | 8.10% |
| 4 | Boston Scientific | 73.63 Bn | 73.09 Bn | 3.85 Bn | 8.16% |
| 5 | Edwards Lifesciences | 52.14 Bn | 47.89 Bn | 1.35 Bn | 40.74% |
| 6 | Dexcom | 34.48 Bn | 32.54 Bn | 830.00 Mn | -2.57% |
| 7 | GE HealthCare Technologies | 34.06 Bn | 31.95 Bn | 2.18 Bn | 2.72% |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | 38.28% |
| 9 | Steris | 23.17 Bn | 22.69 Bn | 684.20 Mn | 32.23% |
| 10 | Nu-Med Plus | 2.03 Mn | 2.02 Mn | - | -43.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79.18% |
| Sep 30, 2025 | 45.84% |
| Mar 31, 2025 | -2.20% |
| Dec 31, 2024 | -41.20% |
| Sep 30, 2024 | -49.75% |
| Jun 30, 2024 | -61.86% |
| Mar 31, 2024 | -64.26% |
| Dec 31, 2023 | -66.95% |
| Sep 30, 2023 | -29.39% |
| Jun 30, 2023 | 69.92% |
| Mar 31, 2023 | 42.49% |
| Dec 31, 2022 | 117.86% |
| Sep 30, 2022 | -75.33% |
| Mar 31, 2022 | -52.23% |
| Dec 31, 2021 | -58.85% |
| Sep 30, 2021 | -42.59% |
| Jun 30, 2021 | -36.79% |
| Mar 31, 2021 | -20.33% |
| Dec 31, 2020 | -18.72% |
| Sep 30, 2020 | -57.47% |